Market Newsdesk

CINCINNATI, Aug. 21, 2023 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero emission commercial vehicles, today filed with the Securities and Exchange Commission (“SEC”) a Prospectus Supplement to its Registration Statement on Form S-3 in connection with the Company’s upcoming Special Meeting scheduled for August 28, 2023.

The Company issued the following statement:

Over the last several weeks, we have been extensively engaging with our stockholders to discuss our proposal to increase the number of our authorized shares of common stock so we can fund our next phase of execution and growth. The Prospectus Supplement updates our S-3 to reflect stockholder input and to make even clearer that we are committed to creating stockholder value when we use it.

We are asking our stockholders to help us build a bridge to long-term growth and stockholder value creation. By voting FOR the proposal, stockholders can enable us to obtain new financing to advance our commercial EV product roadmaps, grow our Aero business and invest in our facilities and other key initiatives.

Workhorse’s Prospectus Supplement can be found at www.sec.gov and at www.VoteWKHS.com.

VOTE TODAY TO SUPPORT WORKHORSE’S PLAN FOR VALUE CREATION

The Special Meeting is scheduled to be held on August 28, 2023. Workhorse stockholders of record at the close of business on July 10, 2023 (the “Record Date”), are entitled to vote at or in advance of the special meeting.

Holders of a majority of ALL our shares of common stock are required to vote in favor of this proposal for it to be approved. Because of this, it is imperative that every stockholder who wants Workhorse to be able to achieve the goals described above vote their shares FOR the proposal today.

Please follow the instructions shown on the proxy card or voting instruction form to vote your shares today. You can vote online or by phone until 11:59 P.M. ET on August 27, 2023. Or you can sign and mail in your proxy card.

Stockholders who have questions or need assistance voting your shares, please contact Morrow Sodali, Workhorse’s proxy solicitor:

Phone: 800-607-0088
[email protected]

Answering Stockholder Questions

Workhorse is holding a webcast to discuss the Special Meeting and answer stockholder questions on August 24, 2023 at 10:00 AM ET, with Workhorse CEO, Rick Dauch, and CFO, Bob Ginnan. Workhorse stockholders can submit questions to [email protected] by 5:00 PM ET on August 23, 2023. To access the webcast, go to www.VoteWKHS.com. A replay will be available for two weeks after the completion of the webcast.

FORWARD LOOKING STATEMENTS

This communication contains certain forward-looking statements within the meaning of federal securities laws with respect to Workhorse Group Inc. (the “Company”), including statements relating to the amendment of our Articles of Incorporation in Nevada and its potential impact on the Company’s ability to obtain financing, build its offerings of commercial electrical vehicles, expand its aerospace business, and capture additional avenues for growth. Forward-looking statements are predictions, projections, and other statements about future events based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in voting and the actual vote counts on the day of the annual meeting; the availability of and need for capital; and the factors, risks and uncertainties regarding the Company’s business described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2023, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023, filed with the SEC on May 15, 2023, and the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023, filed with the SEC on August 14, 2023. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact:

Aaron Palash / Greg Klassen
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Investor Relations Contact:

Matt Glover and Tom Colton
Gateway Investor Relations
949-574-3860
[email protected]

NEWBURYPORT, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) — UFP Technologies, Inc. (Nasdaq: UFPT), an innovative designer and custom manufacturer of components, subassemblies, products, and packaging primarily for the medical market, today announced that Chairman & CEO R. Jeffrey Bailly and Chief Financial Officer Ron Lataille will participate at the Midwest IDEAS Investor Conference on August 23, 2023. UFP Technologies’ presentation is scheduled to begin at 9:20 AM CT on August 23. The presentation will be webcast and can be accessed through the conference site, www.IDEASconferences.com, and in the investor relations section of the company’s website: www.UFPT.com/Investors.

About IDEAS Investor Conferences

The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals. Unlike traditional bank-sponsored events, IDEAS Investor Conferences are “SPONSORED BY INVESTORS. FOR INVESTORS.” and for the benefit of regional investment communities. Conference sponsors collectively have more than $200 billion in assets under management and include: 1102 Partners, Adirondack Research and Management, Allianz Global Investors: NFJ Investment Group, Ariel Investments, Aristotle Capital Boston, Barrow Hanley Mewhinney & Strauss, BMO Global Asset Management, Constitution Research & Management, Inc., Fidelity Investments, First Wilshire Securities Management, Inc., Gamco Investors, Granahan Investment Management, Great Lakes Advisors, Greenbrier Partners Capital Management, LLC, GRT Capital Partners, LLC, Hodges Capital Management, Ironwood Investment Management, Keeley Teton Advisors, Luther King Capital Management, Marble Harbor Investment Counsel, Perritt Capital Management, Punch & Associates, Westwood Holdings Group, Inc., and William Harris Investors.

The IDEAS Investor Conferences are held annually in Boston, Chicago, and Dallas and are produced by Three Part Advisors, LLC. Additional information about the events can be located at www.IDEASconferences.com.

If interested in participating or learning more about the IDEAS conferences, please contact Phillip Kupper at 817-778-8339 or [email protected].

About UFP Technologies, Inc.

UFP Technologies is an innovative designer and custom manufacturer of components, subassemblies, products, and packaging primarily for the medical market. UFP is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The Company’s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.

Contacts:

Ron Lataille, CFO, UFP Technologies, Inc., tel. 978-234-0926
Jeff Elliott, Three Part Advisors, LLC, tel. 214-966-9014

Key Highlights

:

• Advanced clinical development initiatives for Cholesterol Efflux Mediator™ VAR 200, with planned initiation of a Phase 2a clinical trial in diabetic kidney disease (DKD) in the first quarter of 2024
• Granted a European patent covering Phase 2a-ready Cholesterol Efflux Mediator^TM VAR 200 (2-hydroxypropyl-beta-cyclodextrin) for use in diabetic nephropathy/diabetic kidney disease
• Published new white paper detailing the critical role of inflammasome ASC in inflammatory diseases, and the potential of Inflammasome ASC Inhibitor IC 100 to address multiple CNS and non-CNS diseases
• Added Dr. Douglas Golenbock to ZyVersa’s Inflammatory Disease Scientific Advisory Board to support advancement of Inflammasome ASC Inhibitor IC 100

WESTON, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq-GM: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update and reports financial results for the second quarter of 2023 ending June 30, 2023.

“The second quarter of 2023 was a period of continued progress at ZyVersa as we completed key corporate, developmental, regulatory and financial initiatives designed to position the company to achieve value-building milestones involving our Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100,” said Stephen C. Glover, Co-founder, Chairman, Chief Executive Officer, and President of ZyVersa. “We are pleased to report our VAR 200 program is progressing as planned, and we anticipate initiation of a Phase 2a clinical trial in diabetic kidney disease (DKD) in the first quarter of 2024. For our Inflammasome ASC Inhibitor IC 100, we are completing final preclinical activities to enable submission of an Investigational New Drug (“IND”) application and initiation of a first-in-human clinical trial in 2024.”

Mr. Glover concluded: “This is a very exciting time for ZyVersa as we seek to create shareholder value through the development of first-in-class drugs at the forefront of renal and inflammatory diseases. Significant value-building milestones are expected to be achieved for Cholesterol Efflux Mediator^TM VAR 200 and Inflammasome ASC Inhibitor IC 100 over the remainder of 2023 and early 2024 to increase shareholder value.”

SECOND QUARTER AND RECENT PROGRAM UPDATES

Phase 2a-Ready Cholesterol Efflux Mediator™ VAR 200

• European patent was granted covering VAR 200 for use in diabetic nephropathy/diabetic kidney disease
• Planning and key initiatives are underway to initiate a Phase 2a clinical trial in patients with DKD, with initial patient enrollment expected by first quarter 2024

Inflammasome ASC Inhibitor IC 100

• Continued to provide support for the mechanism of action of Inflammasome ASC Inhibitor IC 100 with consistent evidence across peer-reviewed academic literature on the role of inflammasomes in the pathogenesis of a broad range of diseases including Parkinson’s disease, Alzheimer’s disease, lupus nephritis, peripheral arterial disease, juvenile idiopathic arthritis, and alcoholic hepatitis
• Enhanced Inflammatory Disease Scientific Advisory Board with the addition of Dr. Douglas Golenbock, a pioneer and internationally recognized authority in the field of innate immunity
  • Dr. Golenbock is The Neil and Margery Blacklow Chair in Infectious Diseases and Immunology and Professor and Chief, Division of Infectious Diseases and Immunology at the UMass Chan Medical School

SECOND QUARTER FINANCIAL RESULTS

Since its inception in 2014 through June 30, 2023, ZyVersa has not generated any revenue and has incurred significant operating losses and negative cash flows from its operations. Based on our current operating plan, we expect our cash of $0.2 million as of June 30, 2023, will only be sufficient to fund our operating expenses and capital expenditure requirements on a month-to-month basis. ZyVersa will need additional financing to support its continuing operations. ZyVersa will seek to fund its operations through public or private equity or debt financings or other sources, which may include government grants and collaborations with third parties.

Research and development expenses were $1.2 million for the three months ended June 30, 2023, an increase of $0.5 million or 69.7% from the three months ended June 30, 2022. The increase is primarily attributable to an increase of $0.5 million in the costs of manufacturing of IC 100.

General and administrative expenses were $3.9 million for the three months ended June 30, 2023, an increase of $2.8 million or 237.5% from the three months ended June 30, 2022. The increase is primarily attributable to $1.2 million of common stock granted to certain stockholders in exchange for increasing the duration of their lockup period for certain common stockholdings, $0.5 million in professional fees associated with being a public company, a $0.5 million increase in marketing costs for investor and public relations, $0.4 million in director and officer insurance, and $0.2 million for bonus accruals.

Pre-tax losses were $86.3 million for the three months ended June 30, 2023, an increase of $84.3 million compared to a pre-tax loss of approximately $2.0 million, for the three months ended June 30, 2022. The higher net loss reported for the three months ended June 30, 2023 is primarily due to the impairment of in-process research and development and impairment of goodwill of $69.3 million and $11.9 million, respectively, compared to none for the three months ended June 30, 2022. The impairment is a result of the decline in ZyVersa’s market capitalization as of June 30, 2023.

Net losses were $78.5 million for the three months ended June 30, 2023, an increase of $76.5 million compared to a net loss of approximately $2.0 million for the three months ended June 30, 2022. A deferred tax benefit of $7.8 million for the three months ended June 30, 2023, compared to no tax benefit or expense during the three months ended June 30, 2022, resulted from the impairment of the in-process research and development.

About ZyVersa Therapeutics, Inc.

ZyVersa (Nasdaq-GM: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 developed to ameliorate renal lipid accumulation that damages the kidneys’ filtration system in patients with glomerular kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s additional financing and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.

Corporate and IR Contact

Karen Cashmere
Chief Commercial Officer
[email protected]
786-251-9641

Media Contacts

Casey McDonald
[email protected]
646-577-8520

Dave Schemelia
[email protected]
609-468-9325

ZYVERSA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
			Successor
			June 30,				December 31,
			2023				2022
			(Unaudited)
Assets
Current Assets:
	Cash		$	228,693			$	5,902,199
	Prepaid expenses and other current assets			886,911				225,347
	Vendor deposits			–				235,000
		Total Current Assets		1,115,604				6,362,546
Equipment, net				12,133				17,333
In-process research and development				30,806,158				100,086,329
Goodwill				–				11,895,033
Security deposit				–				46,659
Operating lease right-of-use asset				53,898				98,371
		Total Assets	$	31,987,793			$	118,506,271
Liabilities, Temporary Equity and Stockholders’ Equity
Current Liabilities:
	Accounts payable		$	8,144,033			$	6,025,645
	Accrued expenses and other current liabilities			2,281,026				2,053,559
	Operating lease liability			59,625				108,756
		Total Current Liabilities		10,484,684				8,187,960
Deferred tax liability				1,441,467				10,323,983
		Total Liabilities		11,926,151				18,511,943
Commitments and contingencies (Note 8)
	Successor redeemable common stock, subject to possible redemption,
	0 and 65,783 shares outstanding as of June 30, 2023 and
	December 31, 2022, respectively			–				331,331
Stockholders’ Equity:
	Successor preferred stock, $0.0001 par value, 1,000,000 shares authorized:
	Series A preferred stock, 8,635 shares designated, 200 and 8,635 shares issued
	and outstanding as of June 30, 2023 and December 31, 2022, respectively			–				1
	Series B preferred stock, 5,062 shares designated, 5,062 shares issued
	and outstanding as of June 30, 2023 and December 31, 2022			1				1
	Successor common stock, $0.0001 par value, 110,000,000 shares authorized;
	23,669,074 and 9,016,139 shares issued at June 30, 2023 and December 31, 2022,
	respectively, and 23,666,915 and 9,016,139 shares outstanding as of
	June 30, 2023 and December 31, 2022, respectively			2,367				902
	Additional paid-in-capital			107,044,663				104,583,271
	Accumulated deficit			(86,978,221	)			(4,921,178	)
	Treasury stock, at cost, 2,159 and 0 shares at June 30, 2023
	and December 31, 2022, respectively			(7,168	)			–
		Total Stockholders’ Equity		20,061,642				99,662,997
		Total Liabilities, Temporary Equity and Stockholders’ Equity	$	31,987,793			$	118,506,271

ZYVERSA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
			Successor					Predecessor				Successor					Predecessor
			For the Three					For the Three				For the Six					For the Six
			Months Ended					Months Ended				Months Ended					Months Ended
			June 30,					June 30,				June 30,					June 30,
			2023					2022				2023					2022
Operating Expenses:
	Research and development		$	1,220,576				$	719,395			$	2,276,519				$	1,786,357
	General and administrative			3,929,225					1,164,013				7,465,362					3,465,382
	Impairment of in-process research and development			69,280,171					–				69,280,171					–
	Impairment of goodwill			11,895,033					–				11,895,033					–
		Total Operating Expenses		86,325,005					1,883,408				90,917,085					5,251,739
		Loss From Operations		(86,325,005	)				(1,883,408	)			(90,917,085	)				(5,251,739	)
Other (Income) Expense:
	Interest (income) expense			314					140,404				(765	)				308,468
	Change in fair value of derivative liabilities			–					(19,600	)			–					192,500
		Pre-Tax Net Loss		(86,325,319	)				(2,004,212	)			(90,916,320	)				(5,752,707	)
		Income tax benefit		7,812,226					–				8,859,277					–
		Net Loss		(78,513,093	)				(2,004,212	)			(82,057,043	)				(5,752,707	)
		Deemed dividend to preferred stockholders		(7,915,836	)				(331,200	)			(7,915,836	)				(331,200	)
		Net Loss Attributable to Common Stockholders	$	(86,428,929	)			$	(2,335,412	)		$	(89,972,879	)			$	(6,083,907	)
		Net Loss Per Share
		– Basic and Diluted	$	(4.84	)			$	(0.10	)		$	(6.66	)			$	(0.25	)
		Weighted Average Number of
		Common Shares Outstanding
		– Basic and Diluted		17,855,762					24,167,257				13,517,314					24,167,257

WOODCLIFF LAKE, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) a leading provider of innovative and sustainable refrigerant products and services to the Heating, Ventilation, Air Conditioning, and Refrigeration industry–and one of the nation’s largest refrigerant reclaimers–today announced that the Company has repaid in full the remaining principal balance outstanding under its Credit Agreement with TCW Asset Management Company, LLC (“TCW”). In addition, on July 31, 2023 Hudson repaid in full its $15 million first-in-last-out (“FILO”) term loan. Over the last 15 months, the Company has paid down $100 million of term loan and FILO debt combined, resulting in over $10 million of annual savings on interest expense, inclusive of any prepayment fees.  

Hudson’s current Asset Based Lending (“ABL”) facility with Wells Fargo Bank otherwise remains in place and will continue to be utilized primarily for working capital needs, including ensuring the maintenance of adequate inventory balances.

Brian F. Coleman, President and Chief Executive Officer of Hudson Technologies commented, “Our strong operating performance has enabled us to aggressively pay down our debt during the last several quarters, culminating with the full repayment of our term loans, well ahead of the March 2, 2027 maturity date. This repayment will enable us to further reduce interest expense and enhance our leverage ratio. We were very pleased to have a strong partnership with TCW and Wells Fargo as we refinanced our then existing indebtedness during 2022 and look forward to continuing our lending relationship with Wells Fargo. With our proprietary reclamation technology, service and conversion offerings and solid base of customers committed to the adoption of cleaner cooling alternatives, we believe we are well positioned to grow our leadership role in the transitioning refrigerant industry and to capitalize on the tremendous opportunities represented by the ongoing refrigerant phaseouts. We appreciate the support of our lending partners and remain focused on continuing to drive long-term growth and cash flow.”

About Hudson Technologies

Hudson Technologies, Inc. is a leading provider of innovative and sustainable refrigerant products and services to the Heating Ventilation Air Conditioning and Refrigeration industry. For nearly three decades, we have demonstrated our commitment to our customers and the environment by becoming one of the first in the United States and largest refrigerant reclaimers through multimillion dollar investments in the plants and advanced separation technology required to recover a wide variety of refrigerants and restoring them to Air-Conditioning, Heating, and Refrigeration Institute standard for reuse as certified EMERALD Refrigerants™. The Company’s products and services are primarily used in commercial air conditioning, industrial processing and refrigeration systems, and include refrigerant and industrial gas sales, refrigerant management services consisting primarily of reclamation of refrigerants and RefrigerantSide® Services performed at a customer’s site, consisting of system decontamination to remove moisture, oils and other contaminants. The Company’s SmartEnergy OPS® service is a web-based real time continuous monitoring service applicable to a facility’s refrigeration systems and other energy systems. The Company’s Chiller Chemistry® and Chill Smart® services are also predictive and diagnostic service offerings. As a component of the Company’s products and services, the Company also generates carbon offset projects.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained herein which are not historical facts constitute forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to, changes in the laws and regulations affecting the industry, changes in the demand and price for refrigerants (including unfavorable market conditions adversely affecting the demand for, and the price of, refrigerants), the Company’s ability to source refrigerants, regulatory and economic factors, seasonality, competition, litigation, the nature of supplier or customer arrangements that become available to the Company in the future, adverse weather conditions, possible technological obsolescence of existing products and services, possible reduction in the carrying value of long-lived assets, estimates of the useful life of its assets, potential environmental liability, customer concentration, the ability to obtain financing, the ability to meet financial covenants under existing credit facilities, any delays or interruptions in bringing products and services to market, the timely availability of any requisite permits and authorizations from governmental entities and third parties as well as factors relating to doing business outside the United States, including changes in the laws, regulations, policies, and political, financial and economic conditions, including inflation, interest and currency exchange rates, of countries in which the Company may seek to conduct business, the Company’s ability to successfully integrate any assets it acquires from third parties into its operations, the impact of the current COVID-19 pandemic, and other risks detailed in the Company’s 10-K for the year ended December 31, 2022 and other subsequent filings with the Securities and Exchange Commission. The words “believe”, “expect”, “anticipate”, “may”, “plan”, “should” and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

Investor Relations Contact: John Nesbett/Jennifer Belodeau IMS Investor Relations (203) 972-9200 [email protected]		Company Contact: Brian F. Coleman, President & CEO Hudson Technologies, Inc. (845) 735-6000 [email protected]

SANTA CLARA, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) — Today, AMD (NASDAQ: AMD) announced the following events for the financial community:

• Dr. Lisa Su, chair and chief executive officer, will attend the Goldman Sachs 2023 Communacopia and Technology Conference on Tuesday, Sept. 5, 2023, at 11:50 AM EDT/8:50 AM PDT.
• Jean Hu, executive vice president, chief financial officer and treasurer, will attend the Deutsche Bank Technology Conference on Thursday, Aug. 31, 2023, at 11:00 AM EDT/8:00 AM PDT.

A webcast of the presentations can be accessed on AMD’s Investor Relations website ir.amd.com.

About AMD

For more than 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn, Facebook and Twitter pages.

AMD, the AMD Arrow logo and the combination thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

Media Contact:

Drew Prairie
AMD Communications
512-602-4425
[email protected]

Investor Contact:

Mitch Haws
AMD Investor Relations
408-749-3124
[email protected]